These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8487779)

  • 1. A genetically engineered human IgG with limited flexibility fully initiates cytolysis via complement.
    Shopes B
    Mol Immunol; 1993 Apr; 30(6):603-9. PubMed ID: 8487779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A genetically engineered human IgG mutant with enhanced cytolytic activity.
    Shopes B
    J Immunol; 1992 May; 148(9):2918-22. PubMed ID: 1573276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of inter-heavy and light chain disulfide bonds in the effector functions of human immunoglobulin IgG1.
    Dorai H; Wesolowski JS; Gillies SD
    Mol Immunol; 1992 Dec; 29(12):1487-91. PubMed ID: 1454066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of complement by an IgG molecule without a genetic hinge.
    Brekke OH; Michaelsen TE; Sandin R; Sandlie I
    Nature; 1993 Jun; 363(6430):628-30. PubMed ID: 8510754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of the hinge region on complement activation, C1q binding, and segmental flexibility in chimeric human immunoglobulins.
    Tan LK; Shopes RJ; Oi VT; Morrison SL
    Proc Natl Acad Sci U S A; 1990 Jan; 87(1):162-6. PubMed ID: 2296577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human IgG3 can adopt the disulfide bond pattern characteristic for IgG1 without resembling it in complement mediated cell lysis.
    Brekke OH; Bremnes B; Sandin R; Aase A; Michaelsen TE; Sandlie I
    Mol Immunol; 1993 Nov; 30(16):1419-25. PubMed ID: 8232327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flexibility of human IgG subclasses.
    Roux KH; Strelets L; Michaelsen TE
    J Immunol; 1997 Oct; 159(7):3372-82. PubMed ID: 9317136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local and transmitted conformational changes on complexation of an anti-sweetener Fab.
    Guddat LW; Shan L; Anchin JM; Linthicum DS; Edmundson AB
    J Mol Biol; 1994 Feb; 236(1):247-74. PubMed ID: 7893280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification of reduced and alkylated antibody subunits.
    Sun M; Paul S
    Methods Mol Biol; 1995; 51():111-22. PubMed ID: 7581690
    [No Abstract]   [Full Text] [Related]  

  • 10. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells.
    Liu AY; Robinson RR; Hellström KE; Murray ED; Chang CP; Hellström I
    Proc Natl Acad Sci U S A; 1987 May; 84(10):3439-43. PubMed ID: 3106970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a novel modification to monoclonal antibodies: thioether cross-link of heavy and light chains.
    Tous GI; Wei Z; Feng J; Bilbulian S; Bowen S; Smith J; Strouse R; McGeehan P; Casas-Finet J; Schenerman MA
    Anal Chem; 2005 May; 77(9):2675-82. PubMed ID: 15859580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intramolecular signaling upon complexation.
    Guddat LW; Shan L; Fan ZC; Andersen KN; Rosauer R; Linthicum DS; Edmundson AB
    FASEB J; 1995 Jan; 9(1):101-6. PubMed ID: 7821748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The structural requirements for complement activation by IgG: does it hinge on the hinge?
    Brekke OH; Michaelsen TE; Sandlie I
    Immunol Today; 1995 Feb; 16(2):85-90. PubMed ID: 7888072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge.
    Michaelsen TE; Brekke OH; Aase A; Sandin RH; Bremnes B; Sandlie I
    Proc Natl Acad Sci U S A; 1994 Sep; 91(20):9243-7. PubMed ID: 7937748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.
    Dangl JL; Wensel TG; Morrison SL; Stryer L; Herzenberg LA; Oi VT
    EMBO J; 1988 Jul; 7(7):1989-94. PubMed ID: 3138110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human autoantibody recognition of DNA.
    Barbas SM; Ditzel HJ; Salonen EM; Yang WP; Silverman GJ; Burton DR
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2529-33. PubMed ID: 7708679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of heavy and light chain assembly by modification of heavy chain constant region 1 (CH1): Application for the construction of an anti-paclitaxel fragment antigen-binding (Fab) antibody.
    Yusakul G; Sakamoto S; Tanaka H; Morimoto S
    J Biotechnol; 2018 Dec; 288():41-47. PubMed ID: 30389640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering a humanized bispecific F(ab')2 fragment for improved binding to T cells.
    Rodrigues ML; Shalaby MR; Werther W; Presta L; Carter P
    Int J Cancer Suppl; 1992; 7():45-50. PubMed ID: 1428403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric control of antibody-prion recognition through oxidation of a disulfide bond between the CH and CL chains.
    Zhao J; Nussinov R; Ma B
    Protein Eng Des Sel; 2017 Jan; 30(1):67-76. PubMed ID: 27899437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.
    Wang G; de Jong RN; van den Bremer ET; Beurskens FJ; Labrijn AF; Ugurlar D; Gros P; Schuurman J; Parren PW; Heck AJ
    Mol Cell; 2016 Jul; 63(1):135-45. PubMed ID: 27320199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.